agricultural leasing companies vancouver

Boosh Completes Studio Kitchen; Begins Filming Episodes

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) ("Boosh" or the "Company") is pleased to announce that it has completed its studio kitchen located at its greater Vancouver headquarters.

In January 2021, Boosh leased an 8,500 sq ft multi-purpose facility in greater Vancouver. The Company has been building out various aspects of the facility which include corporate offices, dry storage, freezer and refrigerated areas, and its studio which includes its filming kitchen and formal interview areas.

The studio will have interviews and guest appearances from local chefs, vegan athletes, and other trailblazers in the plant-based world. The completed videos and interviews will allow us to grow our online following and share our knowledge of adopting a plant-based lifestyle with individuals that may wish to learn more about alternative, plant-based eating styles.


Some of our regular programming will include:

Cooking with Boosh. This extended series will show how to use our products to create other healthy, nutritionally based meals. As an example, our new Boosh "Good Gravy" can easily be a cornerstone for a vegan holiday meal, and our own Boosh Chili for Chili Cheese Nachos for game day. All of our six frozen and three refrigerated entrées can be combined or adopted to create exceptionally healthy meals.

In addition, Boosh will be presenting "Veggie Hacks" which will be 15 to 30 second spots with unique, quality oriented, delicious plant-based recipes. Items in planning stages include fiery Szechwan green beans, ginger agave glazed carrots, garlic cashew cream alfredo and smokey stuffed portobellos.

In addition, our in-house nutritionist Haley Bellet will be presented, "Mind-Full of Health with Haley". Haley has a passion for food and promoting a healthy living lifestyle. She will be sharing her tips and advice for leading a productive, healthy, and balanced focused life.

"I studied to be a nutritionist and continued to grow my knowledge as the Wellness Manager at Nature's Fare market where I helped people take charge of their personal journey to heal and love, through healthy food choices, supplementation, and other modalities. Nature's Fare was one of the first places you could find delicious Boosh meals which is how I was introduced to Boosh and am absolutely delighted to be part of this amazing, forward thinking, plant loving team," exclaims Haley.

The company has purchased commercial grade equipment including cameras lighting, software, and hardware, as well as retain on a consulting basis a filming and post-edit professional to allow Boosh to produce high quality, visually appealing and education content.

On behalf of the Board of Directors

Jim Pakulis
Chief Executive Officer
Telephone: (833) 882-6674
www.Booshfood.com

Investor Relations
Contact - Edge Communications Group
Email: invest@booshfood.com
Telephone: (236) 237-1315

About Boosh Plant-Based Brands Inc.:

Boosh Plant-Based Brands Inc., through its wholly owned subsidiary, Boosh Food (www.booshfood.com), is the gateway to experiencing high quality, non-GMO, gluten free, 100% plant-based nutritional comfort foods for the whole family. We currently offer six frozen meals which are sold throughout Canada, and now we're expanding our meals to include three refrigerated products. Boosh, good for you and good for planet earth.

The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Forward-looking statements in this news release include, but are not limited to, the Company's proposed use of the proceeds of its initial public offering. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/94844

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Radiopharm Theranostics

Radiopharm Theranostics Receives FDA IND Approval for Phase 2b Imaging Trial in Brain Metastases

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that it has received clearance for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA), for F18-Pivalate (RAD 101).

Keep reading...Show less
Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 NASDAQ Biotech Stocks of 2024

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has traded at three-year highs in the first half of 2024 in response to looming interest rate cuts, breakthrough innovations and increased deals in the space.

After dropping to a low of 3,637.05 in October 2023, the index climbed to start 2024 at 4,457.02. It did hit a bump in the road early in Q2 when it plunged to 4,056.3 in April, but it quickly recovered and has since tracked even higher, reaching 4,634.21 on June 24. But while the current economic environment means the biotech sector may have a complex road ahead, robust growth could be in store in the future.

According to a recent report from Precedence Research, the global biotech market is expected to grow at a compound annual growth rate of 11.8 percent from now to 2033, reaching a valuation of US$4.25 trillion.

Keep reading...Show less
Radiopharm Theranostics

First Patient Dosed with PD-L1 Nanobody in Phase 1 Therapeutic Non-Small Cell Lung Cancer Trial

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the therapeutic dosing of the first patient in its Phase 1 clinical trial of RAD 204, a proprietary nanobody which targets Programmed death-ligand 1 (PD-L1)-positive expression in Non-Small Cell Lung Cancer (NSCLC), the most common type of lung cancer.

Keep reading...Show less
Test tubes.

Can AI Help Detect Cancer? Data Analysis Could Open Up Possibilities for Healthcare Industry

Artificial intelligence (AI) has emerged as a valuable tool for solving complex societal issues, and although it's a new industry, its impact is already being felt in key areas of the life science sector.

AI models in healthcare are quickly advancing beyond basic tasks like medical transcription and administrative streamlining; many systems can now effectively analyze extensive genetic data.

By harnessing AI models' ability to identify patterns and make predictions, medical professionals can institute more effective, personalized treatments and develop precision tests to catch diseases earlier.

Keep reading...Show less
Biotech therapy capsule containing DNA strand surrounded by cells.

Top 3 Canadian Biotech Stocks of 2024

Biotech is a dynamic industry that is driving scientific advancements and innovation in healthcare.

According to Grandview Research, the global biotech market was worth US$1.55 trillion in 2023, and the firm expects it to grow at a CAGR of 13.96 percent between 2024 and 2030 to reach a value of US$3.08 trillion.

In Canada, the biotech industry is home to companies pursuing cutting-edge therapies and medical technologies, and the Investing News Network has identified the top three biotech stocks based on their year-on-year gains.

Keep reading...Show less
Radiopharm Theranostics

Investor Webinar – 3pm AEST Tuesday 2 July

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that CEO and Managing Director Riccardo Canevari and Executive Chairman Paul Hopper will conduct an investor webinar to provide an update following announcement of the Company’s $70 million capital raising.

When: 3pm AEST, Tuesday 2 July 2024

Keep reading...Show less

Latest Press Releases

Related News

×